戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 gments, perivenular hemorrhages, and foci of phlebitis.
2 ration, storiform fibrosis, and obliterative phlebitis.
3  germinal centers, fibrosis and obliterative phlebitis.
4 ns were mainly lymphocytic periphlebitis and phlebitis.
5 cts and ductules, combined with obliterative phlebitis.
6 es, cardiac failure, bleeding diathesis, and phlebitis.
7  cells, storiform fibrosis, and obliterative phlebitis.
8 tic central venous thrombosis was 0.054; arm phlebitis, 0.007; confirmed infection, 0.034; and cathet
9 I 1.26-1.46); and each year increase in age (phlebitis; 0.99 HR, 95% CI 0.98-0.99), (failure; 0.99 HR
10 ion (3.0%), leakage (1.5%), breakage (1.4%), phlebitis (1.2%), and thrombosis (0.5%).
11 /infiltration incidence was 23% (n = 2,767), phlebitis 12% (n = 1,421), and dislodgement 7% (n = 779)
12 .1%), dislodgement (5.0%), occlusion (3.8%), phlebitis (3.4%), and infiltration (1.9%).
13 ng is invasive and associated with a risk of phlebitis and thrombosis.
14 ve lesions, storiform fibrosis, obliterative phlebitis, and accumulation of IgG4-expressing plasma ce
15 asma cells, storiform fibrosis, obliterative phlebitis, and mild to moderate eosinophilia.
16 sma cells, tumefactive lesions, obliterative phlebitis, and mild to moderate eosinophilia.
17 te, superficial, white retinitis; arteritis; phlebitis; and retinal hemorrhages with or without macul
18 ous swelling, eosinophilia, and obliterative phlebitis are other frequently observed features.
19 is, occlusion, pain, infiltration, bleeding, phlebitis, catheter leakage and dislodgement) and whethe
20 ondition characterized by peripheral retinal phlebitis, distal non-perfusion, and neovascularization.
21 ome was all-cause PIVC failure at 12 months (phlebitis, extravasation, obstruction, or infections).
22 ally mild, including (for caspofungin) local phlebitis, fever, abnormal liver function tests, and mil
23 tion/occlusion; HR 1.40, 95% CI 1.27-1.53), (phlebitis; HR 1.36, 95% CI 1.18-1.56), (failure; HR 1.26
24 ilure and complications were: female gender (phlebitis; (HR 1.98, 95% CI 1.72-2.27), (infiltration/oc
25 atheter failure, including mechanical cause, phlebitis, infiltration, pain in relation to drug or flu
26 failure as well as individual complications: phlebitis, infiltration/occlusion, and dislodgement to i
27 use peripheral intravenous catheter failure, phlebitis, occlusion/infiltration, and dislodgement.
28                                      Grade 2 phlebitis occurred in all patients before the use of cen
29                                           No phlebitis or symptomatic venous thrombosis occurred in a
30                                              Phlebitis or thrombophlebitis was more frequent in the p
31 tration, storiform fibrosis and obliterative phlebitis, reflecting a dysregulated immune response aff
32       In neonates, chlorhexidine reduced the phlebitis score compared with non-chlorhexidine-containi
33 val 0.08-0.50); silicone catheters increased phlebitis/thrombophlebitis compared to nonsilicone (one
34 ions (one RCT, RR 0.47, 95%CI 0.31-0.72) and phlebitis/thrombophlebitis in adults (one RCT, RR 0.35,
35 ultrasound-guided catheter insertion reduced phlebitis/thrombophlebitis in adults compared to non-ult
36 ed schedules potentially resulted in a lower phlebitis/thrombophlebitis incidence (10 RCTs; RR, 0.74,
37           Storiform fibrosis or obliterating phlebitis were uncommon pathological findings.